Cuttsy+Cuttsy’s first EcoVadis rating comes back silver!
July 20, 2022 | Environment, Sustainability, What matters to us
Louise Jones, Sustainability Officer at Cuttsy+Cuttsy celebrates their new silver sustainability rating
Over the past year we have been making practical steps to align Cuttsy+Cuttsy to a more sustainable future. Earlier this month, we completed our first voluntary assessment as part of this goal. EcoVadis is a sustainability ratings provider who partner with companies to supply a globally recognised scorecard and performance improvement tools. The submission required a thorough audit across many of our operations, processes, and carbon footprint.
The results are in and Cuttsy+Cuttsy now rate among the top 25 percent of companies assessed by EcoVadis, scoring us a Silver accreditation. As our first submission, this is slightly mind-blowing.
To say I am over the moon would be an understatement. The team and I have worked incredibly hard, and our commitment to sustainability has clearly been reflected. We are incredibly proud of this score, and we are already working on the objectives to achieve Gold.
We are firm believers in better health for everyone and this cannot be achieved without also considering the health of our planet. This is just the first voluntary disclosure we have conducted this year, there will be plenty more to come. Watch this space.
Cuttsy+Cuttsy are committed to a net zero future, and we will achieve this through accurate carbon disclosures and verifiable science-based targets. We will accomplish this, and I look forward to the day when we announce ‘WE DID IT’.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
How to boost clinical trial access and make patients health-empowered
Clinical research is becoming more patient-centric, but there’s still more that needs to be done to make clinical trials available to everyone. This could include wider participation.
Closing the loop: Why clinical trial results matter to participants
Discover why sharing clinical trial results with participants is crucial for respect, informed health decisions, and fostering strong researcher-participant partnerships.
Unveiling the truth: A journey into women’s representation in clinical trials
We explore the historical exclusion of women from clinical trials, its consequences on medical research and treatment efficacy and the ongoing efforts to ensure their representation.
Clarity in clinical trials
Discover how transparent, empathetic communication and health literacy principles can empower patients and enhance engagement in clinical trials, transforming participants into active partners in their healthcare journey.
Caring for patients’ mental health in clinical trials
We look at why ensuring continuous mental health support for patients in clinical trials is essential to enhance their overall well-being and trial engagement.
Driving equitable healthcare: The role of DE&I in clinical trials
Diversity, equity and inclusion (DE&I) is becoming a bigger topic of conversation and meaningful action within clinical trials. And for good reason, too. Find out why we embrace this and…
Empowering patients through more accessible clinical trial information
Senior Medical Writer, Scott Palmer explores the challenges and solutions in enhancing patient engagement in clinical trials, from the pivotal role of healthcare professionals, to the importance of user-friendly trial…
New report now available: Integrating ‘patient first’ into medicine development
A new report has just been published by Cuttsy+Cuttsy that collates all the current best thinking in the ‘patient first’ space, distilling it into a practical and actionable road map…
The digital prescription – enhancing the patient experience with technology
We explore how digital health innovations are revolutionising patient care by enhancing accessibility, personalisation, and engagement, promising a more connected and empowered patient experience.
Compliance — a driving force for influencing public perceptions of the pharma industry?
How does compliance play into public perceptions of pharma and why is it important for improving public opinion?